Suppr超能文献

中高度非霍奇金淋巴瘤生存预后因素的批判性分析。苏格兰和纽卡斯尔淋巴瘤集团治疗工作组

A critical analysis of prognostic factors for survival in intermediate and high grade non-Hodgkin's lymphoma. Scotland and Newcastle Lymphoma Group Therapy Working Party.

作者信息

Hayward R L, Leonard R C, Prescott R J

机构信息

University of Edinburgh, UK.

出版信息

Br J Cancer. 1991 Jun;63(6):945-52. doi: 10.1038/bjc.1991.207.

Abstract

Between 1979 and 1987 the Scotland and Newcastle Lymphoma Group registered 972 adults with Working Formulation high or intermediate grade non-Hodgkin's lymphoma. Clinical, pathological and investigational data were recorded prospectively on a computer database allowing analysis for prognostic factors. We have derived prognostically important characteristics and have tested prospectively the validity of the prognostic index on a geographically distinct sub-set of patients from the Edinburgh/Borders clinics. Multivariate analysis showed the following factors to be important in declining order of power; advancing age, worsening performance status, CNS/liver involvement, abnormal white cell count, 'B' symptoms and advancing clinical stage. Patient individual scores allowed them to be aggregated into one of three distinct prognostic groupings separated by arbitrary cut-points into a Best Group (39%) where the median survival exceeds 5 years (53% alive at 5 years), an Intermediate Group (30%) with median survival of 21 months (21% alive at 5 years), and a Worst Group (31%) whose median survival is 7 months (8% alive at 5 years). Similar prognostic group separations occurred when analysis was confined to: patients younger than 70 years; patients treated with initial chemotherapy; patients treated with initial radiotherapy; patients within any of the major pathological sub-groups.

摘要

1979年至1987年间,苏格兰和纽卡斯尔淋巴瘤研究组登记了972例按工作分类法诊断为高分级或中分级非霍奇金淋巴瘤的成年患者。临床、病理和研究数据前瞻性地记录在计算机数据库中,以便分析预后因素。我们得出了具有预后重要性的特征,并前瞻性地在来自爱丁堡/边境诊所、地理位置不同的患者亚组中检验了预后指数的有效性。多变量分析显示,以下因素按重要性递减顺序排列如下:年龄增长、体能状态恶化、中枢神经系统/肝脏受累、白细胞计数异常、“B”症状和临床分期进展。根据患者个体得分,可将他们归入三个不同的预后分组之一,分组由任意分界点划分:最佳组(39%),中位生存期超过5年(5年时53%存活);中间组(30%),中位生存期为21个月(5年时21%存活);最差组(31%),中位生存期为7个月(5年时8%存活)。当分析局限于以下情况时,也会出现类似的预后分组:年龄小于70岁的患者;接受初始化疗的患者;接受初始放疗的患者;任何主要病理亚组内的患者。

相似文献

本文引用的文献

4
Treatment of diffuse poorly differentiated lymphocytic lymphoma. An analysis of prognostic variables.
Cancer. 1984 Jun 1;53(11):2404-12. doi: 10.1002/1097-0142(19840601)53:11<2404::aid-cncr2820531107>3.0.co;2-f.
8
Current status and perspectives in the treatment of non-Hodgkin's lymphomas.
Eur J Cancer Clin Oncol. 1984 Mar;20(3):305-14. doi: 10.1016/0277-5379(84)90074-9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验